Market Intelligence, Clinical Progress, and High-Purity Reagents for Selective Inhibition Strategies, Antiplatelet Innovation, and Cardiovascular/Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PTGS1 (COX-1) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PTGS1 (COX-1) Recombinant Protein. Full-length, Heme-binding competent, High purity (>95%), Endotoxin <1 EU/μg. Sequence Verified. HEK293 Expressed. | View PTGS1 Products |
| Gene Delivery | PTGS1 Promise-ORF / Lentivirus. Full-length ORF for stable cell line construction. | View PTGS1 Products |
| Benchmark Ab | Anti-PTGS1 (COX-1) Monoclonal Antibody. Recombinant positive control for Western blot and IHC. | View PTGS1 Products |
| Validator | PTGS1 siRNA Set. For knockdown verification and specificity control. | View PTGS1 Products |
| Mechanistic Mutant | PTGS1 S530A Mutant Protein. Aspirin-acetylation resistant variant for irreversible inhibition mechanism studies. | View PTGS1 Products |
| Benchmark Control | NSAID Reference Standards (Indomethacin, SC-560). For assay standardization and positive controls. | View PTGS1 Products |
| Related Target (Selectivity) | PTGS2 (COX-2) Recombinant Protein. Ortholog for counter-screening, HEK293 Expressed, >95% purity. | View PTGS2 Products |
| Downstream Partner | TBXA2R (Thromboxane A2 Receptor). For antiplatelet efficacy validation assays. | View TBXA2R Products |
| Related Target | PTGES (mPGES-1). Downstream prostaglandin pathway partner for combination studies. | View PTGES Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (COX-1 vs COX-2) | Human PTGS1 and PTGS2 ortholog proteins available with >95% purity for strict counter-screening; matched panel for parallel IC50 determination. |
| Homodimer Stability & Heme Incorporation | HEK293 expressed (native glycosylation), Theoretical MW validated, Endotoxin <1 EU/μg, suitable for Oxygen Consumption Assays. |
| Irreversible Inhibition Kinetics | S530A Mutant included for acetylation-site mechanism validation; distinguishes covalent vs. reversible binders. |
| Membrane Protein Localization | Lentivirus premade particles for stable, native cell line construction. |
| Lack of Reliable Controls | Sequence-verified Recombinant benchmark antibodies and siRNA included for assay normalization and batch-to-batch consistency. |
| False Positives / Off-Target Risk | Validated siRNA for target-engagement confirmation in PGE2 production and cell-based inhibitor assays. |
| Enzymatic Activity Standardization | Sequence Verified catalytic domain; compatible with PGE2 ELISA and arachidonic acid substrate turnover assays. |
Live PTGS1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic landscape surrounding COX-1 (PTGS1) has evolved from broad-spectrum NSAIDs to precision modulation. Modern drug discovery predominantly uses COX-1 as a critical counter-screening target, while the next wave of R&D pursues selective COX-1 inhibitors for antiplatelet therapy with reduced gastrointestinal liability and novel applications in oncology and neurodegeneration. Developing highly selective COX-2 inhibitors requires rigorous profiling against COX-1 to predict gastrointestinal safety profiles and platelet effects. As first-generation therapies mature, the next phase targets precision modulation through tissue-specific delivery systems (e.g., intestinal-targeted formulations) and allosteric modulation. Emerging programs are exploring time-dependent kinetics and gene polymorphism-guided personalized therapy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (NSAID) | Bayer, Pfizer, Horizon Therapeutics | Cardiovascular, Pain, Osteoarthritis | Selectivity Assay (PTGS1 vs PTGS2 IC50 ratio) using high-purity ortholog proteins |
| Reformulated NSAID (NODDs) | NicOx, AlfaSigma | GI-safe analgesia | Time-dependent Inhibition Kinetics (Reversible vs Irreversible mechanisms) |
| PROTACs | Arvinas (Pathway analogs) | Inflammation | Degradation Assays (Need HEK293 Expressed targets) |
| Gene Therapy | Academic Spin-offs | Rare bleeding disorders | Expression Validation (Need specific Abs) |
| Selective COX-1 Inhibitor | NCI-designated labs, Academic consortia | Colorectal Cancer, Neuroblastoma | IC50 Selectivity Panel (Need purified WT & Mutant PTGS1 vs PTGS2) |
| Combination Therapy | AstraZeneca, Takeda, Oncology biotechs | Gastric protection, Solid Tumors | Cell-based PGE2 Assay; Compound Stability in gastric milieu |